Certificate under Regulation 74 (5) of SEBI (DP) Regulations, 2018 for the 3rd Quarter ended 31st December, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Welcure Drugs & Pharmaceuticals has submitted a routine compliance certificate to BSE for the third quarter ended 31 December 2025. The certificate was issued by the company's Registrar and Transfer Agent, Skyline Financial Services Pvt Ltd, as required under SEBI's Depository Participants Regulations. It confirms that no physical share certificates were received from any depository participant for dematerialization during the quarter. The filing was signed by Managing Director & CFO Chintan Didawala Ganpat on 5 January 2026. This is a standard quarterly compliance submission with no financial or operational numbers involved.
This is a routine regulatory filing with no material impact on shareholders or stock price. It simply confirms that no physical shares were submitted for dematerialization in the October–December 2025 quarter, indicating the company's shares continue to be held in demat form as expected.